Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10983663 | 0.86 | MEN1 (0.58) | KMT2ACYP2C19MEN1CYP1A2HTT | |
| SCHEMBL2303474 | 0.86 | MEN1 (0.58) | KMT2ACYP2C19MEN1CYP1A2HTT | |
| SCHEMBL27496188 | 0.82 | KMT2A (0.50) | KMT2ACYP2C19MEN1CYP1A2HTT | |
| SCHEMBL8807366 | 0.81 | CYP2C19 (0.53) | KMT2ACYP2C19MEN1CYP1A2HTT | |
| SCHEMBL69791 | 0.81 | HTT (0.69) | KMT2ACYP2C19MEN1CYP1A2HTT | |
| SCHEMBL6440734 | 0.81 | MEN1 (0.56) | KMT2ACYP2C19MEN1CYP1A2HTT | |
| SCHEMBL17582660 | 0.81 | MEN1 (0.56) | KMT2ACYP2C19MEN1CYP1A2HTT | |
| SCHEMBL24479152 | 0.80 | ALDH1A1 (0.54) | KMT2ACYP2C19MEN1CYP1A2HTT | |
| SCHEMBL28582917 | 0.80 | MEN1 (0.51) | KMT2ACYP2C19MEN1CYP1A2HTT | |
| SCHEMBL27262022 | 0.80 | TDP1 (0.44) | KMT2AMEN1ALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| WO-2017035114-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | KMT2A 3436/4885CYP2C19 503/4885MEN1 3980/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | KMT2A 3421/4885CYP2C19 487/4885MEN1 3963/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | KMT2A 3421/4885CYP2C19 487/4885MEN1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.